SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Heuer V. B.)
 

Search: WFRF:(Heuer V. B.) > Diagnostic value of...

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Thijssen, E. H. (author)
La Joie, R. (author)
Wolf, A. (author)
show more...
Strom, A. (author)
Wang, P. (author)
Iaccarino, L. (author)
Bourakova, V. (author)
Cobigo, Y. (author)
Heuer, H. (author)
Spina, S. (author)
VandeVrede, L. (author)
Chai, X. Y. (author)
Proctor, N. K. (author)
Airey, D. C. (author)
Shcherbinin, S. (author)
Evans, C. D. (author)
Sims, J. R. (author)
Zetterberg, Henrik, 1973 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Blennow, Kaj, 1958 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Karydas, A. M. (author)
Teunissen, C. E. (author)
Kramer, J. H. (author)
Grinberg, L. T. (author)
Seeley, W. W. (author)
Rosen, H. (author)
Boeve, B. F. (author)
Miller, B. L. (author)
Rabinovici, G. D. (author)
Dage, J. L. (author)
Rojas, J. C. (author)
Boxer, A. L. (author)
show less...
 (creator_code:org_t)
2020-03-02
2020
English.
In: Nature Medicine. - : Springer Science and Business Media LLC. - 1078-8956 .- 1546-170X. ; 26, s. 387-397
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Plasma pTau181 concentrations are elevated specifically in patients diagnosed with Alzheimer's disease compared to those diagnosed with frontotemporal lobar degeneration or elderly controls, supporting its further development as a blood-based biomarker for AD. With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid beta positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid beta-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by F-18-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.

Subject headings

NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Keyword

positron-emission-tomography
neurofilament light-chain
mild cognitive
impairment
csf biomarkers
association workgroups
national institute
fluid biomarkers
amyloid pet
dementia
neuropathology
Biochemistry & Molecular Biology
Cell Biology
Research & Experimental
Medicine

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view